N-Acetylcysteine Treatment for Drug-Induced Hepatic Failure

Initiation and Administration

Treatment should be initiated as soon as possible after suspected drug-induced liver injury, regardless of the causative agent, according to the American Society of Anesthesiologists 1, 2
NAC therapy should be started without waiting for confirmatory laboratory results when drug-induced hepatic failure is suspected, as recommended by the American College of Medical Toxicology 3

NAC has shown benefit in non-acetaminophen-related acute liver failure, with improved transplant-free survival (41% versus 30%, OR = 1.61, 95% CI 1.11–2.34, P = 0.01), as reported by the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2
A meta-analysis of adult patients demonstrated improvements in overall survival (76% versus 59%, OR = 2.30, 95% CI 1.54–3.45 P <0.0001) and liver transplant-free survival (64% versus 26%, OR = 4.81, 95% CI 3.22–7.18, P < 0.0001), according to the American Association for the Study of Liver Diseases 1
NAC should be initiated early in the course of drug-induced hepatic failure, as its beneficial effects appear to be greater in patients with early-stage hepatic encephalopathy (grades I-II), as recommended by the European Association for the Study of the Liver 2

Monitor for adverse effects, which may include nausea, vomiting, diarrhea, skin rash (< 5%), or transient bronchospasm (1-2%), as reported by the American Academy of Clinical Toxicology 1, 2
Delaying NAC administration while awaiting laboratory confirmation can reduce its efficacy; treatment should be initiated promptly when drug-induced hepatic failure is suspected, according to the American College of Emergency Physicians 1, 3

The recommended IV NAC regimen is 150 mg/kg loading dose over 15 minutes, followed by 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours, as suggested by the American Gastroenterological Association 4, 5
For oral administration, a loading dose of 140 mg/kg followed by 70 mg/kg every 4 hours for 17 doses can be used, according to clinical guidelines 5

Monitor liver function tests including AST, ALT, alkaline phosphatase, and total bilirubin during NAC therapy 5
Track coagulation parameters including INR and PT during treatment, to assess the effectiveness of NAC 5
The American Gastroenterological Association recommends that NAC be used only in the context of clinical trials for non-acetaminophen-associated acute liver failure, although recent evidence suggests benefit in non-acetaminophen cases 4
Consider NAC administration even when the cause of acute liver failure is uncertain, as it may be beneficial and has minimal toxicity, with a low risk of adverse reactions such as nausea and vomiting 4

The quality of evidence for NAC in non-acetaminophen acute liver failure is lower than for acetaminophen-induced cases, with a need for further clinical trials to establish its efficacy 4